Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)

NCT00731653 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

OTHER

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: Combination Product: BCI-024 + BCI-049

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]